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Aim To examine the risk factors, comorbidity, severity of 
liver disease, treatment course, and outcome in Croatian 
war veterans with chronic hepatitis C, especially those suf-
fering from posttraumatic stress disorder (PTSD).
Methods We collected medical records of 170 adult men 
diagnosed with chronic hepatitis C who started treatment 
with a combination of pegylated interferon-alpha and rib-
avirin between January 2003 and June 2009 at the Croa-
tian Reference Centre for Viral Hepatitis.
Results Participants’ mean age was 43 ± 9 years. Among 
170 participants, there were 37 war veterans (22%). The 
main risk factor in veteran patients were operative pro-
cedures with transfusions (46% vs 5% in non-veterans; 
P < 0.001) and in non-veteran patients intravenous drug 
use (42.1% vs 13%; P < 0.001). The average duration of in-
fection was longer in war veterans (14.5 ± 3.4 vs 12.2 ± 7.2 
years; P = 0.020). The percentage of PTSD comorbidity in 
the whole group was 11% (18/170) and in the war veter-
ans group 49% (18/37). The prevalence of sustained viro-
logical response in patients with PTSD was 50% and in pa-
tients without PTSD 56%. Treatment reduction in patients 
with PTSD (33%) was higher than in patients without PTSD 
(12%; P = 0.030).
Conclusion Croatian war veterans are a group with high 
risk of chronic hepatitis C infection because many of them 
were wounded during the Croatian War 1991-1995. Con-
siderations about PTSD as a contraindication for interfer-
on treatment are unjustified. If treated, patients with PTSD 
have an equal chance of achieving sustained virological re-
sponse as patients without PTSD.
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Infectious diseases have historically been responsible for 
the majority of war-related deaths; however, medical and 
military advances have reversed this trend and today mili-
tary health care is confronted with specific medical issues 
related to war veterans’ social, psychological, and epide-
miological characteristics. Chronic hepatitis C (CHC) has 
in the recent years been identified as the single most im-
portant emerging pathogen in the war veterans’ health 
care system.
Military veterans are at risk of acquiring viral hepatitis 
through training and combat (field bleeding, surgery, and 
transfusions). Several studies conducted in the USA have 
shown a higher prevalence of hepatitis C virus (HCV) infec-
tion in veterans than in the general population (1-4). The 
US Department of Veteran Affairs reported a 3-fold preva-
lence of HCV seropositivity in war veterans (6.6%) than in 
the general population (2%) (1,3).
Effective treatment of CHC with pegylated interferon-al-
pha (PEG-IFN-α) and ribavirin, as measured by sustained 
virological response (SVR), eradicates the virus in 40%-
50% of patients infected with HCV genotype 1 and ap-
proximately 80% of patients with genotypes 2 or 3 (5,6). 
Even with major advances in the treatment of CHC, only 
a minority of HCV-infected people (up to 30%) are pre-
scribed treatment in the real-life setting. Butt et al (2) re-
ported a treatment prescription rate of 11.8% in 113 927 
US veterans with CHC. The major barriers to the initiation 
of antiviral therapy were high rates of psychiatric comor-
bidities, substance use, and standard well-established 
predictors of poor virological response (male sex, alcohol 
abuse, overweight, and older age).
Significant proportion of veterans experiences moderate 
to severe depressive symptoms. El-Serag et al (7) showed 
that 33.5% of 33 824 US veterans with CHC were diagnosed 
with posttraumatic stress disorder (PTSD). Although recent 
studies suggested that psychiatric disorders should not be 
considered as an absolute contraindication for interferon-
based therapy, these patients are less likely to initiate and 
successfully complete the treatment (8-10). CHC treatment 
can be compromised by a variety of neuropsychiatric 
symptoms such as fatigue, irritability, depression, anxiety, 
and psychosis, which either limit the administered doses of 
drugs or lead to a discontinuation of treatment, reducing 
the probability of achieving SVR (5,6,11).
During the Croatian War 1991-1995, there were approx-
imately 12 000 killed and 35 000 wounded. Out of 
30 520 wounded (7163 civilians and 23 351 soldiers), 84.5% 
were surgically treated, mostly before 1993, ie, before the 
routine introduction of blood donor anti-HCV screening in 
Croatia (12). The reported prevalence of PTSD in Croatian 
war veterans ranges between 16% and 34% (13,14), but no 
systematic studies on HCV seroprevalence in Croatian war 
veterans have been performed so far. Consequently, HCV 
infection and CHC in this neglected population remain an 
important public health issue.
The primary aim of this study was to examine the risk fac-
tors, comorbidity, and severity of liver disease, treatment 
course, and SVR in Croatian war veterans compared with 
the general male population. As PTSD is recognized as 
the most important comorbidity among war veterans, 
the second aim was to compare the course of PEG-IFN-α 
and ribavirin treatment in patients with PTSD and pa-
tients without PTSD.
PArtIcIPANtS AND methoDS
Participants
This retrospective study included 170 adult men diag-
nosed with CHC who started treatment with a combi-
nation of PEG-IFN-α and ribavirin between January 2003 
and June 2009 at the Croatian Reference Centre for Viral 
Hepatitis, Ministry of Health and Social Welfare of the Re-
public of Croatia and Department of Viral Hepatitis, Uni-
versity Hospital for Infectious Diseases (UHID), Zagreb, 
Croatia. The mean age of the patients was 43 ± 9 years 
and weight was 82 ± 9 kg. The group comprised 37 war 
veterans (21.7%). The prevalence of PTSD comorbidity 
was 10.6% in the whole group (18/170) and 48.6% (18/37) 
among war veterans. All patients with PTSD were receiv-
ing psychiatric care at baseline (before the initiation of 
antiviral therapy) and throughout the study period. They 
were diagnosed with combat-related PTSD by their cur-
rent psychiatric clinician (according to the 10th revision 
of the International Classification of Diseases). A total 
of 125 patients were treated with Peg-IFN-α2a 180 μg/
week + ribavirin and 45 were treated with Peg-IFN-α2b 
1.5 μg/week + ribavirin. Ribavirin was administered in the 
recommended doses, according to weight. The duration 
of therapy in HCV genotypes 1 and 4 was 48 weeks, and 
in genotypes 2 and 3 was 24 weeks. The therapy was dis-
continued in patients with genotype 1 and genotype 4 if 
viral load decreased by less than 2 log HCV RNA copies/
mL at week 12 compared with baseline values and if HCV 
RNA was still detectable at week 24.
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method and definitions
Croatian war veterans and general male population were 
compared according to demographic data, risk factors, 
genotypes, duration of infection, and type of pegylated 
interferon. The patients were classified into three groups: 
war veterans, war veterans with PTSD, and male popula-
tion without PTSD. Patients who had SVR and who discon-
tinued treatment or required a reduction of therapeutic 
doses with and without PTSD were also compared.
SVR was defined as undetectable HCV RNA at 24 weeks af-
ter the end of antiviral therapy. HCV RNA quantification was 
performed by COBAS Ampliprep/COBAS TaqMan HCV test 
(Roche Diagnostics, Diagnostic Systems, Pleasanton, CA, 
USA). HCV genotyping was performed by VERSANT HCV 
Genotyping assay (LIPA, Bayer Diagnostics, Puteaux, Cedex, 
France) at the Department of Molecular Diagnostics and 
Cellular Immunity, UHID. Liver biopsy was performed at the 
Department of Viral Hepatitis, UHID and the Ishak scoring 
system (15) was used as an indicator of histological activity 
(stages of fibrosis from 0-6, where 0 represents no fibrosis 
and 6 represents established cirrhosis).
Data collection
The study was approved by the Ethics Committee of the 
UHID. Records of all men treated at the Department of Vi-
ral Hepatitis, UHID during the study period were extracted 
and used for collection of clinical and laboratory data. Viro-
logical results obtained from patient records were double-
checked at the database of the Department of Molecular 
Diagnostics and Cellular Immunity, UHID. Liver biopsy was 
performed at the UHID, and histological analysis was per-
formed by a skilled pathologist at the Zagreb University 
Hospital. Liver biopsy data were double-checked at the da-
tabase of the Department for Viral Hepatitis, UHID. The pa-
tients underwent psychiatric evaluation in order to assess 
their eligibility for CHC treatment, as required by the Croa-
tian Institute for Health Insurance. Data on PTSD comorbid-
ity was collected from psychiatry medical records. Disease 
duration was calculated from the date of blood transfusion 
before 1993, the date of severe operation, or the time of 
the drug injection that was the onset of infection.
Statistical analysis
The baseline demographic, clinical, and laboratory data 
were evaluated and presented descriptively. Fisher exact 
test and Wilcoxon rank sum test were used to compare the 
two groups as appropriate. Reduction rate, cessation of 
therapy, and SVR were compared using χ2 and Fisher exact 
test as appropriate. Statistical analysis was performed using 
Prism statistical software, version 5.0, (GraphPad Software, 
San Diego, CA, USA). All comparisons were two tailed, and 
P < 0.05 was considered significant.
reSuLtS
Patient characteristics
A total of 170 patients were included in the study. War vet-
erans and participants from the general male population 
showed similar demographic, clinical, and virological char-
acteristics (Table 1).
There were significant differences between the two groups 
in transmission routes. The main risk factor among war vet-
erans were operative procedures with transfusions (45.9% 
vs 5.3%; P < 0.001, Fisher exact test) and among non-veter-
ans intravenous drug use (42.1% vs 13.5%; P < 0.001). Dura-
tion of infection was longer among war veterans (14.5 ± 3.3 
tABLe 1. Baseline characteristics of 170 patients with chronic 
hepatitis c (37 veteran and 133 non-veteran)
No. (%) of 
war veterans
No. (%) of 
non-veterans P
Age, years 45 ± 8 42 ± 11  0.041*
Weight, kg 80 ± 16 82 ± 11  0.699*
risk factor:
unknown  5 (13.5) 35 (26.3)  0.127†
operation  7 (8.1)  5 (3.7)  0.005†
transfusion  1 (2.7) 25 (18.7)  0.018†
operation and transfusion 17 (45.9)  7 (5.3) <0.001†
intravenous drug use  5 (13.5) 56 (42.1) <0.001†
wounding  2 (5.4)  3 (2.2)  0.298†
sex  2 (1.5)
Genotype:
1 25 (67.6) 92 (69.2)  0.843†
2  1 (2.7)  1 (0.7)  0.389†
3 10 (27.0) 38 (28.6) >0.950†
4  1 (2.7)  2 (1.5)  0.524†
Liver biopsy (Ishak score, mean ± standard deviation):‡
fibrosis  3.44 ± 1.05  3.45 ± 1.06  0.884*
histology activity score  8.81 ± 3.37  8.28 ± 2.90  0.586*
Duration of infection, years: 14.5 ± 3.38 12.2 ± 7.17  0.020*
treatment:
pegylated interferonα2a 30 (81.1) 95 (71.4)  0.295†
pegylated interferonα2b  7 (18.9) 38 (28.5)  0.295†
*Wilcoxon rank sum test.
†Fisher exact test.
‡Ishak et al (15).
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vs 12.2 ± 7.1 years; P = 0.020, Wilcoxon rank sum test). Both 
groups had similar genotype, liver biopsy result, age, 
weight, and type of pegylated interferon (Table 1).
reduction and discontinuation of therapy
The therapy was reduced or discontinued in 155 of the 170 
patients. The remaining patients had unavailable or incom-
plete medical records.
Dose reduction was more frequent in patients without 
PTSD than in those with PTSD (Table 2). There were no sig-
nificant differences in discontinuation of therapy, although 
patients with PTSD had somewhat more frequent discon-
tinuations.
The main reasons for discontinuation were depression and 
severe psychiatric disorders that required hospitalization. 
The main reasons for dose reduction were severe anemia, 
leukopenia, thrombocytopenia, anxiety, and depression 
symptoms that were not satisfactorily resolved with anti-
depressants.
Virological response in patients with and without PtSD
Analyses included data from all patients who received at 
least one dose of medication (intention to treat analysis). 
In the whole group of CHC patients, SVR was achieved 
in 96 out of 170 patients (56.4%). SVR rate for genotype 
1 and 4 was 47% and for genotype 2 and 3 was 74%. In 
the subgroup of war veterans, 21 of 37 patients (56.7%) 
achieved SVR.
In order to determine the influence of PTSD comorbidity 
on virological response, several clinical parameters were 
compared between patients with PTSD and without PTSD 
and no significant differences were found (Table 2). How-
ever, 4 patients with PTSD (22.2%) did not finish the pro-
tocol, 3 for safety reasons due to serious side effects and 1 
due to non-safety reasons (loss to follow-up). In the group 
of patients without PTSD, 22 (14.5%) did not finish the pro-
tocol; 10 due to adverse effects, 3 due to poor virological 
response, and 9 due to loss to follow-up.
DIScuSSIoN
To our knowledge, this is the first study describing the out-
come of CHC treatment in war veterans in Croatia. War vet-
erans represented 21% of the male population receiving 
therapy from January 2003 to July 2009 at the UHID, ac-
counting for a significant part of HCV-infected population. 
The main risk factors were major operation with transfu-
sions and intravenous drug use, which is the major trans-
mission route among the general male population.
Croatian War 1991-1995 brought considerable military ca-
sualties (16). The majority of approximately 23 000 wound-
ed soldiers were operated on several times with trans-
fusion, exposing them to substantial CHC risk (12,17). 
According to the World Heath Organization, the estimat-
ed prevalence of HCV infection in Croatia is 1.4%, however 
it is higher among war veterans and other war casualties 
(18,19).
High risk of CHC was first recognized in Vietnam War vet-
erans from the USA. However, they differed considerably 
from the participants of this study – were older and had 
more psychiatric, alcohol, and drug abuse disorders, and 
lower virological responses (1,3,4,20). Other studies on 
USA veterans have also reported different results than 
tABLe 2. treatment modification and sustained virological response (SVr) in participants with posttraumatic stress disorder (PtSD) 
(N = 18) and without it (N = 137 for treatment modification, 152 for SVr)
No. (%) of patients
with PtSD without PtSD P*
Treatment modification 6 (33.3)† 17 (12.4)‡  0.030
Pegylated interferon-α dose reduction 2 (11.1)  8 (5.8)  0.327
Ribavirin dose reduction 3 (16.7)  5 (3.6)  0.051
Pegylated interferon-α and ribavirin dose reduction 1 (5.5)  4 (2.9)  0.465
Treatment discontinuation 3 (16.6) 10 (7.3)  0.178
Sustained virological response (intention-to-treat analysis) 9 (50.0) 87 (57.2)  0.619
Lost to follow-up 1 (5.5)  9 (5.9) >0.950
*Fisher exact test.
†reasons for treatment modification: anemia or/and neutropenia, n = 3; depression, n = 2; psychosis, n = 1.
‡reasons for treatment modification: anemia, neutropenia or/and thrombocytopenia, n = 7; depression, n = 4; prolonged rash and itch, n = 2; hypo-
thyroidism, n = 1; non-safety reasons, n = 3.
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our study. Butt et al (21) reported the completion rate of 
22.5% among 16 043 veterans-in-care, compared with 83% 
among patients with PTSD in our study. Nguyen et al (20) 
found intravenous drug use to be the most common risk 
factor in the USA war veterans, 60% of whom had psychi-
atric diagnoses. The incidence of PTSD in the USA HCV-in-
fected war veterans was 19%-34% (7,20), which is similar 
tour study (48.6%). This is also similar to earlier Croatian 
studies that have reported up to 34% prevalence of PTSD 
or PTSD with a comorbid psychiatric diagnosis among Cro-
atian war veterans (13,14).
War veterans with psychiatric disorder have been denied 
treatment for HCV infection, mainly because interferon 
treatment may worsen the underlying psychiatric illness, 
resulting in premature discontinuation of antiviral treat-
ment and non-compliance (8,9), especially since PTSD is 
a disorder linked with substantial distress and dysfunction. 
CHC has been found to provoke exacerbation of PTSD and, 
together with interferon, cause hyperarousal and re-ex-
periencing of symptoms, thus complicating the course of 
treatment (8,11).
Our study revealed a higher rate of treatment modification 
and discontinuation in patients with PTSD than in patients 
without PTSD, mainly due to psychiatric disorders, which fi-
nally resulted in a slightly lower SVR in patients with PTSD 
than in patients without PTSD. However, according to previ-
ously published evidence (8-10) and this study, the majority 
of patients with PTSD can be treated safely and effectively, 
and have an equal chance to achieve SVR as patients with-
out PTSD. Furthermore, our war veterans mainly stopped 
treatment for safety reasons, exhibited better compliance 
than general male population, and only a minority missed 
the follow-up 24 weeks after the end of treatment.
The main limitation of this study is a retrospective nature of 
the collected data and a limited number of patients. How-
ever, this was the maximum number of patients that we 
could have collected since the study was performed in the 
largest treatment center for HCV-positive patients in Cro-
atia. Most of the data from medical charts were double-
checked in available databases, which reduced potential 
biases caused by lacking or incomplete documentation. 
Furthermore, all patients met the eligibility criteria for treat-
ment according to the Croatian Institute for Health Insur-
ance, resulting in more detailed medical charts than usual.
This is the first report on HCV infection among Croatian war 
veterans, the true prevalence of which in Croatia is still un-
known, and further screening and public health programs 
are necessary to elucidate the true scope of this problem. 
The high rate of PTSD comorbidity requires the develop-
ment of multidisciplinary treatment models that would 
provide coordinated mental health and medical care for 
patients with CHC. Finally, a successful antiviral treatment 
is needed to decrease the transmission of HCV in the gen-
eral population.
In summary, Croatian war veterans have a high risk of CHC, 
especially those with PTSD comorbidity. Our data showed 
that these patients had an equal chance of achieving SVR, 
and therefore PTSD comorbidity should not be considered 
an exclusion criterion for interferon treatment.
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